Treatment of Joints pain with Unani medicine Habbe Gule Aak and Roghane Hina

Clinical validation of an Unani pharmacopeial formulation Habbe Gule Aak & Roghane Hina Vs Majoon Jograj Goggul & Roghan Malkangani for local application in Waja ul Mafasil (Rheumatoid Arthritis) - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070679

Enrollment

106

Registered

2024-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Habbe Gule Aak and Roghan e Hina: 1 Tab(250mg) orally to be taken with water twice daily and Oil to be applied locally on affected area respectively for 12 weeks Intervention2: Roghan e

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-60 2. Patients fulfilling the ACR criteria for rheumatoid arthritis

Exclusion criteria

Exclusion criteria: 1. Patients having Gout, or complicated rheumatoid arthritis associated with deformity. 2. Abnormality in any investigation done at baseline (SGOT, SGPT and ALP, Sr Creatinine, B. Urea would be considered abnormal if raised more than 2 and half times the normal value), also Patients with GFR less than 60 will be exclude from the study. 3. Severe cases of RA (Stage III & IV) & diagnosed cases of ankylosing spondylosis will be excluded from the study. 4. Patient with High grade fever will be excluded from the study 5. Disorders requiring long term treatment 6. Cases with systemic manifestation of Rheumatoid arthritis 7. Patient is on treatment for any illness related to Endocrine & metabolic disorders 8. Drug addicts (Alcohol, drugs) 9. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
The efficacy of the study drug in the treatment of Waja ul Mafasil (Rheumatoid Arthritis) will be assessed on the basis of Reduction of the 2010 ACR-EULAR Rheumatoid Arthritis Classification Criteria scores from baseline to the end visit of the Study. Timepoint: On each fortnight for 12 weeks	—

Secondary

Measure	Time frame
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and 12 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ghazala.javed@gov.in9811810454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026